
Browsing restrictions can be lifted for a fee.
6.28%
Bristol-myers squibb company ce
-3.61%
Avg of Sector
-2.16%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Bristol-myers squibb company ce (CELG-RI) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CELG-RI's short-term business performance and financial health. For the latest updates on CELG-RI's earnings releases, visit this page regularly.
According to historical valuation range analysis, Bristol-myers squibb company ce (CELG-RI)'s current price-to-earnings (P/E) ratio is 0.03, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, Bristol-myers squibb company ce (CELG-RI) reported an Operating Profit of 3.63B with an Operating Margin of 29.05% this period, representing a growth of 43.5% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Bristol-myers squibb company ce (CELG-RI) announced revenue of 12.5B, with a Year-Over-Year growth rate of 1.3%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Bristol-myers squibb company ce (CELG-RI) had total debt of 48.97B, with a debt ratio of -4.23. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Bristol-myers squibb company ce (CELG-RI) held Total Cash and Cash Equivalents of 10.21B, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Bristol-myers squibb company ce (CELG-RI) achieved the “three margins increasing” benchmark, with a gross margin of 91.77%%, operating margin of 28.06%%, and net margin of 8.69%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CELG-RI's profit trajectory and future growth potential.
According to the past four quarterly reports, Bristol-myers squibb company ce (CELG-RI)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.53. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Bristol-myers squibb company ce (CELG-RI)'s Free Cash Flow (FCF) for the period is 1.6B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 60.5% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Bristol-myers squibb company ce (CELG-RI) has a Price-To-Earnings (PE) ratio of 0.03 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.